Welcome to our dedicated page for Cryoport SEC filings (Ticker: CYRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cryoport, Inc. (CYRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Cryoport submits annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with exhibits such as earnings press releases. These documents outline its temperature-controlled supply chain business for the life sciences, its segment structure, risk factors, and detailed financial results.
For example, a recent Form 8-K filing reported the release of Cryoport’s financial results for a completed quarter, attaching the related press release as an exhibit. Such current reports typically summarize revenue from continuing operations, contributions from Life Sciences Services and Life Sciences Products, gross margins, operating expenses, and other key metrics. They may also describe items such as impairment charges, discontinued operations, and the impact of strategic transactions.
On this page, users can review filings that discuss Cryoport’s support for clinical and commercial cell and gene therapies, its global operations across the Americas, EMEA, and APAC, and its capital allocation activities, including share repurchase programs. Forms 10-K and 10-Q provide more extensive narrative on the company’s integrated supply chain platform, including biologistics, biostorage, bioservices, cryogenic systems, and related offerings.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy reports, helping readers quickly understand segment performance, material events, and changes in guidance. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and other filings appear promptly, while insider transaction reports on Form 4 and proxy materials, when available, can be used to analyze executive and director activity and governance matters.
Cryoport, Inc. files its annual report describing a focused strategy as a global provider of temperature-controlled supply chain solutions for life sciences, with emphasis on the fast‑growing cell and gene therapy market. As of December 31, 2025, the company supported 760 clinical trials and 20 commercially approved cell and gene therapies.
Cryoport reports two segments: Life Sciences Services, which generated 54.8% of 2025 revenue through BioLogistics, BioStorage, BioServices and cryopreservation offerings, and Life Sciences Products, where cryogenic systems manufacturing contributed 45.2%. Revenue is concentrated in the Americas, which accounted for 74.5% of 2025 sales, with EMEA at 14.3% and APAC at 11.2%.
In 2025 Cryoport completed the divestiture of its CRYOPDP specialty courier business to DHL affiliates for $133.0 million, plus repayment of approximately $77.2 million of intercompany loans, and entered a master partnership aimed at strengthening presence in EMEA and APAC. One Life Sciences Services customer represented 10.2% of 2025 revenue, highlighting some customer concentration risk.
The report details heavy investment in digital platforms (Cryoportal, Smartpak, Tec4med IoT, the planned MVE CryoVerse ecosystem) and quality frameworks like Chain of Compliance and multiple ISO and GMP certifications. It also outlines extensive risk factors, including supply chain dependence on key components, product liability (particularly in reproductive medicine and biostorage), foreign currency exposure, cyber‑security threats, regulatory complexity and potential goodwill and intangible asset impairments.
Cryoport, Inc. reported solid growth for 2025 with improving profitability trends. Full-year revenue reached $176.2 million, exceeding the high end of prior guidance and rising 12% year-over-year, while fourth-quarter revenue grew 10% to $45.5 million. Life Sciences Services revenue increased 18% to $96.5 million and Life Sciences Products revenue grew 7% to $79.7 million. Gross margin for 2025 was 47%, supported by cost reduction initiatives and a $12 million year-over-year improvement in adjusted EBITDA from continuing operations to a loss of $5.8 million.
Cryoport’s position in cell and gene therapy strengthened, with revenue from commercial CGT support up 29% to $33.4 million and clinical trial support revenue up 14% to $47.1 million. The company backed 760 global clinical trials at year-end, including 86 in Phase 3, and supported 20 commercial therapies. After the CRYOPDP divestiture and strategic partnership with DHL, cash and cash equivalents rose to $250.5 million and short-term investments to $160.7 million. For 2026, Cryoport issued revenue guidance of $190 million to $194 million.
Brown Capital Management, LLC filed an amended Schedule 13G reporting its beneficial ownership of Cryoport, Inc. common stock. The firm is deemed to beneficially own 1,112,771 shares, representing 2.22% of the outstanding common stock as of the event date 12/31/2025.
Brown Capital reports sole voting power over 1,110,308 shares and sole dispositive power over 1,112,771 shares, with no shared voting or dispositive power. All shares are held in accounts of its investment advisory clients, with Brown Capital treated as beneficial owner under Rule 13d-3 due to its discretionary authority. The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Cryoport.
Cryoport, Inc. has a new large shareholder disclosure. Investment entities Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of about 3.2 million shares of Cryoport common stock, representing 6.5% of the outstanding class as of December 31, 2025.
The reporting parties state they share voting and dispositive power over these shares and certify the position was not acquired to change or influence control of Cryoport, but instead is held on a passive basis under Schedule 13G rules.
Cryoport, Inc. filed its quarterly report, showing higher revenue and stronger margins alongside a major portfolio shift. Q3 revenue reached $44.233M, up from $38.317M, driven by gains in both Life Sciences Services ($24.258M) and Life Sciences Products ($19.975M). Gross margin improved to $21.325M, while loss from operations narrowed to $(9.932)M. Q3 net loss was $(6.943)M (basic and diluted $(0.18) per share).
Year-to-date, revenue was $130.727M vs. $115.317M last year. Results reflect the June 11 divestiture of the CRYOPDP specialty courier business to DHL for $133.0M plus repayment of $77.2M intercompany loans, recorded as discontinued operations and producing a $120.047M gain. This drove nine‑month net income of $89.945M, despite a continuing‑operations loss of $(25.448)M.
Liquidity strengthened: cash and cash equivalents were $255.811M and short‑term investments were $165.503M, totaling $421.314M. Total liabilities fell to $261.057M, stockholders’ equity rose to $513.271M, and the 2025 Convertible Senior Notes were repaid ($14.344M). Shares outstanding were 50,068,904 as of October 31, 2025.
Cryoport, Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states this information is being furnished and is not deemed filed under Section 18 of the Exchange Act. The filing was signed by Chief Financial Officer Robert Stefanovich on November 4, 2025.
Cryoport, Inc. Schedule 13G filing discloses that Integrated Core Strategies (US) LLC reports beneficial ownership of 2,555,766 shares and Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 2,562,717 shares of Cryoport common stock, representing 5.1% of the class for each Millennium-related reporting person. The filing, reflecting an event date of 09/24/2025 and signed 09/25/2025, shows shared voting and dispositive power (no sole voting or dispositive power). The participants submitted a Joint Filing Agreement as Exhibit I.
CryoPort, Inc. (CYRX) Form 144 notice reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $242,737.50, to be sold approximately on 09/11/2025 on NASDAQ. The shares were acquired and will be sold the same day pursuant to an exercise of options under a registered plan. The filing also records a prior sale by Robert Hariri of 5,000 shares on 08/22/2025 for $43,000. The filer certifies no undisclosed material information.
Robert J. Hariri, a director of Cryoport, Inc. (CYRX), reported a sale of 5,000 shares of the company's common stock on 08/22/2025 at a reported price of $8.60 per share. Following this transaction he beneficially owned 26,275 shares, held directly. The Form 4 discloses only this non-derivative sale and contains no additional explanation.
Robert Stefanovich, Chief Financial Officer of Cryoport, Inc. (CYRX), reported option exercises and a sale on 08/19/2025. He exercised 26,164 stock options with an exercise price of $3.07, producing 26,164 shares. To cover the exercise cost, he sold 9,300 shares in multiple transactions at a weighted-average price of $8.6686 (individual sale prices ranged from $8.60 to $8.75). After these transactions he beneficially owned 207,213 shares. The option grant vests 1/48 each month beginning August 19, 2015.